Intellipharmaceutics International Stock Revenue
| IPCIFDelisted Stock | USD 0.04 0.00 0.00% |
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Revenue Analysis
Intellipharmaceutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Intellipharmaceutics International reported 0.0 of revenue. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Intellipharmaceutics Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in revenue category among its peers.
Intellipharmaceutics Fundamentals
| Return On Asset | -0.98 | ||||
| Operating Margin | (106.06) % | ||||
| Current Valuation | 4.47 M | ||||
| Shares Outstanding | 33.09 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 11.09 % | ||||
| Number Of Shares Shorted | 714 K | ||||
| Price To Earning | (0.50) X | ||||
| Price To Sales | 66.19 X | ||||
| Gross Profit | 1.4 M | ||||
| EBITDA | (4.45 M) | ||||
| Net Income | (5.15 M) | ||||
| Cash And Equivalents | 79.65 K | ||||
| Total Debt | 2.01 M | ||||
| Debt To Equity | 165.20 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.31) X | ||||
| Cash Flow From Operations | (2.46 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Target Price | 25.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 2.1 M | ||||
| Retained Earnings | (86.55 M) | ||||
| Working Capital | (5.62 M) | ||||
| Current Asset | 1.41 M | ||||
| Current Liabilities | 7.02 M | ||||
| Z Score | -65.8 | ||||
| Net Asset | 2.1 M |
About Intellipharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Intellipharmaceutics International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellipharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellipharmaceutics International based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |